Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial.

Zubizarreta I, Flórez-Grau G, Vila G, Cabezón R, España C, Andorra M, Saiz A, Llufriu S, Sepulveda M, Sola-Valls N, Martinez-Lapiscina EH, Pulido-Valdeolivas I, Casanova B, Martinez Gines M, Tellez N, Oreja-Guevara C, Español M, Trias E, Cid J, Juan M, Lozano M, Blanco Y, Steinman L, Benitez-Ribas D, Villoslada P.

Proc Natl Acad Sci U S A. 2019 Apr 23;116(17):8463-8470. doi: 10.1073/pnas.1820039116. Epub 2019 Apr 8.

2.

Naturally produced type I IFNs enhance human myeloid dendritic cell maturation and IL-12p70 production and mediate elevated effector functions in innate and adaptive immune cells.

Sköld AE, Mathan TSM, van Beek JJP, Flórez-Grau G, van den Beukel MD, Sittig SP, Wimmers F, Bakdash G, Schreibelt G, de Vries IJM.

Cancer Immunol Immunother. 2018 Sep;67(9):1425-1436. doi: 10.1007/s00262-018-2204-2. Epub 2018 Jul 13.

3.

Tolerogenic Dendritic Cells as a Promising Antigen-Specific Therapy in the Treatment of Multiple Sclerosis and Neuromyelitis Optica From Preclinical to Clinical Trials.

Flórez-Grau G, Zubizarreta I, Cabezón R, Villoslada P, Benitez-Ribas D.

Front Immunol. 2018 May 31;9:1169. doi: 10.3389/fimmu.2018.01169. eCollection 2018. Review.

4.

Corrigendum: Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma.

Benitez-Ribas D, Cabezón R, Flórez-Grau G, Molero MC, Puerta P, Guillen A, González-Navarro EA, Paco S, Carcaboso AM, Santa-Maria Lopez V, Cruz O, de Torres C, Salvador N, Juan M, Mora J, Morales La Madrid A.

Front Oncol. 2018 Jun 5;8:201. doi: 10.3389/fonc.2018.00201. eCollection 2018.

5.

Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma.

Benitez-Ribas D, Cabezón R, Flórez-Grau G, Molero MC, Puerta P, Guillen A, Paco S, Carcaboso AM, Santa-Maria Lopez V, Cruz O, de Torres C, Salvador N, Juan M, Mora J, La Madrid AM.

Front Oncol. 2018 Apr 26;8:127. doi: 10.3389/fonc.2018.00127. eCollection 2018. Erratum in: Front Oncol. 2018 Jun 05;8:201.

6.

Up-regulation of EP2 and EP3 receptors in human tolerogenic dendritic cells boosts the immunosuppressive activity of PGE2.

Flórez-Grau G, Cabezón R, Borgman KJE, España C, Lozano JJ, Garcia-Parajo MF, Benítez-Ribas D.

J Leukoc Biol. 2017 Sep;102(3):881-895. doi: 10.1189/jlb.2A1216-526R. Epub 2017 Jun 19.

PMID:
28630103
7.

Nanoencapsulated budesonide in self-stratified polyurethane-polyurea nanoparticles is highly effective in inducing human tolerogenic dendritic cells.

Flórez-Grau G, Rocas P, Cabezón R, España C, Panés J, Rocas J, Albericio F, Benítez-Ribas D.

Int J Pharm. 2016 Sep 25;511(2):785-93. doi: 10.1016/j.ijpharm.2016.07.056. Epub 2016 Jul 28.

PMID:
27477102
8.

MERTK as negative regulator of human T cell activation.

Cabezón R, Carrera-Silva EA, Flórez-Grau G, Errasti AE, Calderón-Gómez E, Lozano JJ, España C, Ricart E, Panés J, Rothlin CV, Benítez-Ribas D.

J Leukoc Biol. 2015 Apr;97(4):751-60. doi: 10.1189/jlb.3A0714-334R. Epub 2015 Jan 26.

Supplemental Content

Loading ...
Support Center